24 reports

  • Global cervical cancer market
  • Global pancreatic cancer drugs market
  • Breast Cancer
  • Cancer
  • Therapy
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.

The most common cancers in 2016 are projected to be breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis

  • Cancer
  • Cancer Diagnostic
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • LUNG CANCER THERAPEUTICS MARKET IN EMEA
  • GROWING APPROVALS IN LUNG CANCER THERAPEUTICS MARKET
  • Cancer
  • Lung Cancer
  • AstraZeneca PLC
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
  • F. HOFFMANN-LA ROCHE: YOY GROWTH AND REVENUE GENERATED FROM NET PRODUCT SALES OF AVASTIN 2011-2014 ($ BILLIONS)
  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly
  • Vendor landscape

PART ##: Disease overview TYPES OF GASTRIC CANCER Gastric cancer is one of the common types of cancer.

  • Cancer
  • Gastric Cancer
  • Therapy
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Vendor landscape
  • Geographical segmentation

Breast cancer is the leading cause of cancer deaths in women in underdeveloped countries and the second leading cause of cancer deaths in developed countries.

  • Cancer
  • United States
  • World
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • 05. Introduction
  • 19.1 Competitive Scenario

The Colon Cancer Alliance in the US, Society of Gastroenterology Nurses and Associates, Fight Colorectal Cancer, Bowel Cancer Australia, Bowel Cancer UK, American Cancer Society, and Singapore Cancer Society are some of the organizations engaged

  • Cancer
  • United States
  • World
  • Forecast
  • F. Hoffmann-La Roche Ltd.

Breast cancer is the most common form of cancer occurring in the female population across the world.

  • Cancer
  • Diagnostics
  • Abbott Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PHASE I, 2015
  • Caspase 3 for Oncology
  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • Therapy
  • F. Hoffmann-La Roche Ltd.

Cancer caused by tobacco, lung cancer, is the most common type of cancer, which is a burden in low- and middle-income countries.

  • Cancer
  • Diagnostics
  • DNA
  • Abbott Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Global HER-2 Positive Breast Cancer Market
  • 08.3 HER-2 POSITIVE BREAST CANCER MARKET IN US
  • Breast Cancer
  • Cancer
  • World
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • 18.1 Competitive Scenario
  • 18.2 Market Share Analysis 2014

It has launched three new medicines to fight breast and blood cancer and also explored new ways of using the immune system to tackle cancer.

  • Brain Cancer
  • Cancer
  • Therapy
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Clinical Trial Profiles
  • Prominent Sponsors

IT IS USED FOR THE TREATMENT OF OVARIAN CANCER, UTERINE CANCER, ACUTE LEUKEMIA, MALIGNANT LYMPHOMA HEAD AND NECK CANCER, BREAST CANCER, STOMACH CANCER AND UROTHELIAL CANCER PIRARUBICIN IS A TOPOISOMERASE II INHIBITOR.

  • Bladder Cancer
  • Cancer
  • Clinical Trial
  • Hospital
  • F. Hoffmann-La Roche Ltd.
  • Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for
  • Clinical Trial Details

In addition, It is indicated for reducing the incidence of breast cancer in women at high risk for breast cancer.

  • Cancer
  • Clinical Trial
  • Drug Discovery And Development
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Global Kidney Cancer Drugs Market
  • 19.1 COMPETITIVE SCENARIO
  • Cancer
  • United States
  • World
  • Forecast
  • F. Hoffmann-La Roche Ltd.
  • Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
  • IMMU-132
  • Cancer
  • Colorectal Cancer
  • Therapy
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Clinical Trial Profiles
  • LOCATION(S)/SPONSOR(S) SPONSOR(S)/COLLABORATOR(S) - TYPE & DETAILS

Bevacizumab (RG##) is under development for the treatment of fallopian ovarian cancer, epethelial ovarian cancer and peritoneal cancer, intracranial meningioma, locally advanced/ metastatic well-differentiated digestive endocrine tumors, relapsed or refractory neurobl

  • Cancer
  • Clinical Trial
  • Adaptimmune Therapeutics plc
  • F. Hoffmann-La Roche Ltd.
  • Threshold
  • 06.2 PATHOPHYSIOLOGY
  • 07.1 MARKET OVERVIEW
  • Breast Cancer
  • Cancer
  • Therapy
  • Market Segment
  • F. Hoffmann-La Roche Ltd.
  • TOP COMPANIES PARTICIPATING IN METASTATIC BREAST CANCER THERAPEUTICS CLINICAL TRIALS
  • Clinical Trial profile. 31 Trial Title
  • Cancer
  • Clinical Trial
  • Drug Discovery And Development
  • Therapy
  • F. Hoffmann-La Roche Ltd.
  • TOP COMPANIES PARTICIPATING IN GASTRIC CANCER THERAPEUTICS CLINICAL TRIALS
  • Clinical Trial profile. 77 Trial Title
  • Cancer
  • Clinical Trial
  • Therapy
  • World
  • F. Hoffmann-La Roche Ltd.
  • Children's Cancer and Leukaemia Group and F. Hoffmann-La Roche Ltd have conducted highest number of ependymoma clinical trials.
  • As of August 2017, Children's Cancer and Leukaemia Group and F. Hoffmann-La Roche Ltd sponsored the highest number of ependymoma clinical trials.
  • Brain Cancer
  • Cancer
  • Pathology
  • World
  • F. Hoffmann-La Roche Ltd.
  • Clinical Trial profile. 80 Trial Title
  • 5. All the trials included are unique trials.

Lurie Comprehensive Cancer Center of Northwestern University ## May 1995 ## May 1998 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Star

  • Cancer
  • Clinical Trial
  • Leukemia
  • Monoclonal Antibody
  • F. Hoffmann-La Roche Ltd.

The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $## million and major research centers in HIV/ AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, gen

  • Cancer
  • Genetic Disorder
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.
  • Clinical Trial profile. 111 Trial Title
  • Clinical Trial Profile Snapshots

CANCER RESEARCH UK; UNIVERSITY COLLEGE LONDON BLOODWISE LIMITED ## JAN 2009 ## ## ## DNA SYNTHESIS INHIBITOR DNA A PHASE I/ II TRIAL OF RITUXIMAB, BENDAMUSTINE, AND OBATOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN' S LYMPHOMA OBATOCLAX MESYLATE, RITUXIMAB, AND BEN

  • Cancer
  • Clinical Trial
  • Lymphoma
  • World
  • F. Hoffmann-La Roche Ltd.